Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Jiangsu Hengrui Pharmaceuticals CoSHSE:600276 -0.87%91 Return-on-Tangible-Equity is 16.50% as of Mar. 2026, which is 17% below its 10-year median of 19.77. GuruFocus rates SHSE:600276 with a GF Score™ of 91/100 and a GF Value™ of ¥60.77 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 899 Drug Manufacturers companies, Jiangsu Hengrui Pharmaceuticals Co ranks better than 71.75% on this metric.
The historical rank and industry rank for Jiangsu Hengrui Pharmaceuticals Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:600276'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 11.17 Med: 19.77 Max: 24.21
Current: 15.72
During the past 13 years, Jiangsu Hengrui Pharmaceuticals Co's highest Return-on-Tangible-Equity was 24.21%. The lowest was 11.17%. And the median was 19.77%.
SHSE:600276's Return-on-Tangible-Equity is ranked better than 71.75% of 899
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs SHSE:600276: 15.72
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Jiangsu Hengrui Pharmaceuticals Co Return-on-Tangible-Equity Related Terms
Jiangsu Hengrui Pharmaceuticals Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jiangsu Hengrui Pharmaceuticals Co Return-on-Tangible-Equity Chart
SHSE:600276 vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Jiangsu Hengrui Pharmaceuticals Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Jiangsu Hengrui Pharmaceuticals Co Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Jiangsu Hengrui Pharmaceuticals Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Jiangsu Hengrui Pharmaceuticals Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 16.50% mean?
Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) has a Return-on-Tangible-Equity of 16.50% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. This is 17% below median its historical median of 19.77. Over the past decade, Jiangsu Hengrui Pharmaceuticals Co's Return-on-Tangible-Equity has ranged from 11.17 to 24.21. According to the industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #254 out of 899 companies in the Drug Manufacturers industry, placing it in the top 28.3%.
Is Jiangsu Hengrui Pharmaceuticals Co's Return-on-Tangible-Equity too high?
Jiangsu Hengrui Pharmaceuticals Co's current Return-on-Tangible-Equity of 16.50% is 17% below median its 10-year median of 19.77. Over the past 10 years, this metric has ranged from a low of 11.17 to a high of 24.21. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Jiangsu Hengrui Pharmaceuticals Co's value of 16.50% is 108.9% above this industry median. Based on the distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #254 out of 899 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Jiangsu Hengrui Pharmaceuticals Co has a GF Score™ of 91/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Jiangsu Hengrui Pharmaceuticals Co's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Jiangsu Hengrui Pharmaceuticals Co ranks #254 out of 899 companies for Return-on-Tangible-Equity. This puts Jiangsu Hengrui Pharmaceuticals Co in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Jiangsu Hengrui Pharmaceuticals Co's value of 16.50% is 108.9% above this benchmark. Historically, Jiangsu Hengrui Pharmaceuticals Co's own Return-on-Tangible-Equity has ranged from 11.17 to 24.21 over the past decade. While the company's 10-year median is 19.77 vs. the industry median of 7.90, Jiangsu Hengrui Pharmaceuticals Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 899 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Jiangsu Hengrui Pharmaceuticals Co's current Return-on-Tangible-Equity of 16.50% is 108.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Jiangsu Hengrui Pharmaceuticals Co and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Jiangsu Hengrui Pharmaceuticals Co's current Return-on-Tangible-Equity is 16.50%, which is 17% below median its own 10-year median of 19.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Jiangsu Hengrui Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥60.77, compared to a current price of ¥54.91 — trading 9.6% below its estimated fair value. The current Return-on-Tangible-Equity is 16.50%, which is 17% below median its 10-year median of 19.77 and 108.9% above the Drug Manufacturers industry median of 7.90. Jiangsu Hengrui Pharmaceuticals Co's overall GF Score™ is 91/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276), the current Return-on-Tangible-Equity is 16.50% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Jiangsu Hengrui Pharmaceuticals Co (SHSE:600276) Overvalued in 2026?
Based on GuruFocus' analysis, Jiangsu Hengrui Pharmaceuticals Co stock appears to be undervalued.
The current stock price of ¥54.91 is trading 9.6% below its estimated GF Value™ of ¥60.77.
GuruFocus considers Jiangsu Hengrui Pharmaceuticals Co to be Modestly Undervalued.
Key valuation signals for SHSE:600276:
Return-on-Tangible-Equity: 16.50% (17% below median its 10-year median of 19.77)
GF Value™: ¥60.77 vs. price of ¥54.91 (9.6% below fair value)
Industry Position: 108.9% above the Drug Manufacturers median (#254 of 899)
No single metric tells the full story. See the SHSE:600276 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Jiangsu Hengrui Pharmaceuticals Co Business Description
Jiangsu Hengrui Pharmaceuticals Co Ltd is a biopharmaceutical company that engages in the research, development, manufacture, and sale of drugs. It is engaged in the field of cancer treatment drugs, surgical medicines, endocrine therapy drugs, cardiovascular drugs, and anti-infection medications. The company specializes in the research and development of new medicines in areas of antineoplastics, endocrine system, cardiovascular, and the immune system. Geographically, the company is segmented as Chinese mainland and Other countries generating majority revenue from the Chinese region.
91GF Score
Get the complete analysis for SHSE:600276
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600276 has been successfully added to your 
